Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 157, Issue 4, Pages 446-456Publisher
WILEY
DOI: 10.1111/j.1365-2141.2012.09078.x
Keywords
MECOM; BCR-ABL1; tyrosine kinase; imatinib; chronic myeloid leukaemia
Categories
Funding
- GCU
- Leukaemia & Lymphoma Research project [08018]
- Glasgow Experimental Cancer Medicine Centre (ECMC)
- Cancer Research UK
- Chief Scientist's Office (Scotland)
Ask authors/readers for more resources
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately reduces BCR-ABL1 mRNA and protein expression but not tyrosine kinase catalytic activity in K562 cells. We also show that both E and ME are expressed in CD34+ selected cells of both CML chronic phase (CML-CP), and non-CML (normal) origin. Furthermore, MECOM mRNA and protein expression were repressed by imatinib mesylate treatment of CML-CP CD34+ cells, K562 and KY01 cell lines whereas imatinib had no effect in non-CML BCR-ABL1 -ve CD34+ cells. Together these results suggest that BCR-ABL1 tyrosine kinase catalytic activity regulates MECOM gene expression in CML-CP progenitor cells and that the BCR-ABL1 oncoprotein partially mediates its biological activity through MECOM. MECOM gene expression in CML-CP progenitor cells would provide an in vivo selective advantage, contributing to CML pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available